Weisleder Pedro
Department of Neurology, The Children's Medical Center of Dayton, One Children's Plaza, Dayton, OH 45404-1815, USA.
J Am Acad Psychiatry Law. 2007;35(3):317-22.
In a recent publication, the lack of consensus among U.S. laws regarding the age at which minors may consent to confidential treatment for abuse of illegal substances was highlighted. This article reports the results of an investigation of the information used by legislators to determine the age at which minors may consent to treatment. Evidence indicates that in four states lawmakers considered the advice of mental health professionals before making age determinations. In six states "consistency with other state laws" or "precedence" was the lawmakers' major consideration. In five states, the main concern was removing legal barriers to treatment access. Lawmakers from several states had no independent recollection regarding the motives behind age selection. When deciding on the age at which minors would be allowed to consent to substance abuse treatment, some state legislators based their decisions on clinical data or legal facts. Some, however, appear to have made decisions without a clear foundation.
在最近的一份出版物中,强调了美国法律在未成年人可同意接受非法药物滥用保密治疗的年龄问题上缺乏共识。本文报告了一项关于立法者用于确定未成年人可同意治疗年龄的信息的调查结果。证据表明,在四个州,立法者在确定年龄之前考虑了心理健康专业人员的建议。在六个州,“与其他州法律的一致性”或“先例”是立法者的主要考虑因素。在五个州,主要关注点是消除治疗准入的法律障碍。几个州的立法者对年龄选择背后的动机没有独立的记忆。在决定允许未成年人同意药物滥用治疗的年龄时,一些州立法者基于临床数据或法律事实做出决定。然而,有些人似乎是在没有明确依据的情况下做出决定的。